Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Strive, Inc. posted a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc. The notice states Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive.
A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval. The communication emphasizes forward‑looking statement cautions and clarifies it is not an offer to sell or solicit the purchase of securities. Documents will be available on the SEC’s website and the companies’ investor sites.
Strive, Inc. filed a communication under Rule 425 about its proposed business combination with Semler Scientific, Inc. (SMLR). The notice includes a forward‑looking statements disclaimer and outlines required SEC materials.
Strive intends to file a Form S-4 to register the Class A common stock to be issued in the transaction. An Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval. The document also identifies potential solicitation participants and explains how investors can access SEC filings.
Semler Scientific (SMLR) and Strive, Inc. filed a Form 425 communication tied to their proposed business combination. The notice, reposted on X by Strive’s Chief Legal Officer, contains forward-looking statements and cautions about related risks. Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus. Semler Scientific stockholders will receive definitive materials to vote on the deal. Documents will be available on the SEC website and the companies’ investor sites. This is not an offer to sell securities.
Strive, Inc. issued a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive plans to file a Form S-4 to register Class A common stock to be issued in connection with the transaction, which will include an information statement/proxy statement/prospectus.
Semler Scientific stockholders will receive definitive materials to vote on the proposed transaction. The notice includes cautionary forward-looking statements and clarifies it is not an offer or solicitation to sell securities.
Strive, Inc. reposted a Rule 425 communication about its proposed business combination with Semler Scientific, Inc. (SMLR). Strive plans to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus for Semler stockholders.
A definitive proxy will be sent to Semler stockholders to seek approval. Related documents will be available free on the SEC’s website and the companies’ investor sites. The notice emphasizes forward-looking statement risks and clarifies this is not an offer to sell or solicit any security.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive intends to file a Form S-4 to register Class A common stock to be issued in connection with the transaction, and a combined information statement/proxy statement/prospectus will be sent to Semler stockholders to seek their approval.
The notice includes standard forward‑looking statements, identifies potential solicitation participants, and states this is not an offer or solicitation to buy or sell securities.
Strive, Inc. filed a Rule 425 communication regarding its proposed business combination with Semler Scientific, Inc.
Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, with an Information Statement/Proxy Statement/Prospectus to be sent to Semler Scientific stockholders to seek their approval. The communication includes forward-looking statement cautions and directs investors to the SEC’s website and the companies’ investor pages for the Registration Statement and related materials when available.
Strive, Inc. filed a Form 425 communication about its proposed business combination with Semler Scientific, Inc. The notice states Strive intends to file a Form S-4 to register Class A common stock to be issued in connection with the transaction, which will include an information statement/proxy statement/prospectus.
A definitive proxy will be sent to Semler Scientific stockholders to seek their approval. The communication includes cautionary forward-looking statements and a standard “no offer or solicitation” disclaimer, directing investors to future SEC filings for full details.
Strive, Inc. posted a communication regarding its proposed business combination with Semler Scientific, Inc. (SMLR). The notice includes a forward‑looking statements disclaimer and outlines next steps for the transaction process.
Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus. Semler Scientific stockholders will receive proxy materials to vote on the proposed transaction. This communication is not an offer to sell or solicit the purchase of securities.
Strive, Inc. announced a proposed business combination with Semler Scientific and outlined next steps in the regulatory process. Strive intends to file an S-4 registration statement to register Class A common stock to be issued in the transaction, which will include an information statement, proxy statement for Semler Scientific stockholders, and a prospectus.
A definitive proxy/prospectus will be sent to Semler Scientific stockholders to seek approval of the proposed transaction. The communication includes a standard caution about forward-looking statements and directs investors to review the S-4 and related materials when available on the SEC’s website and the companies’ investor sites.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
